Observational studyFrontiers in immunology2026
Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Refractory ocular myasthenia gravis (OMG) remains a significant therapeutic challenge with limited evidence-based biologic therapies. This study aimed to evaluate the effectiveness and safety of telitacicept, a recombinant B-lymphocyte stimulator receptor-antibody fusion protein, in refractory OMG. Methods: This retrospective, single-center observational study assessed clinical outcomes, immunological biomarkers, and safety following add-on telitacicept therapy in refractory OMG. Disease severity was evaluated using the Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Impairment Index (MGII) scales. Serum immunoglobulins, complement components, and CD19 Results: Twelve patients with refractory OMG were included. Median baseline MG-ADL, QMG, and MGII scores were 5.5 (interquartile range [IQR] 5.0-6.0), 7.0 (IQR 5.3-8.0), and 16.0 (IQR 12.0-18.0), respectively. Statistically significant improvement was observed as early as week 1 (all Conclusion: Telitacicept was associated with rapid, sustained clinical improvement and a favorable safety profile in refractory OMG, which supports its potential role as an add-on therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.